On October 29, 2018, the Luxembourg Institut National du Cancer (INC) launched MDLUX2, a molecular diagnostics program with a goal of "improving the effectiveness of cancer treatment whilst supporting cancer research." It is believed that this program will allow further analysis of tumours and determine potential clinical trials that a patient may benefit from.
To learn more about MDLUX2, click here
No comments:
Post a Comment